



Admedus Limited
ABN 35 088 221 078

REGISTERED OFFICE:
26 Harris Road
Malaga Western Australia 6090

Customer Service:
T 1300 550 310
F 1300 880 398

International:
T +61 (0)8 9266 0100
F +61 (0)8 9266 0199
E info.au@admedus.com
www.admedus.com

ASX ANNOUNCEMENT

2 November 2017

ADMEDUS RESPONDS TO MEDIA SPECULATION

MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) (**Company** or **Admedus**) notes the recent media speculation about the ongoing funding of Admedus Vaccines Pty Ltd and the Admedus Immunotherapies (**AI**) business run by it. That speculation suggests there has been a change in strategy by Admedus with respect to the ongoing funding of AI.

In fact, there has been no change in the Company's approach to AI to that previously disclosed to ASX. As stated in the release to ASX of Admedus' FY2017 financial results on 31 August 2017, AI has funding for the coming financial year. In that announcement, Admedus also stated that: *'The board of AI are currently undertaking a review of the potential strategic options available to them to secure the continuing development of AI's technologies in a manner that balances maximising their potential with returns for its shareholders.'*

That position has not changed. Admedus remains the majority shareholder in Admedus Vaccines and will continue to explore options in respect of AI in order to return value to shareholders.

The Company also notes that AI does not contribute to the Company's revenue in a material way and confirms that it is in compliance with ASX Listing Rule 3.1 (Continuous Disclosure).

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research and development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com



Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Admedus Limited

Barb Ferres

+61 7 3152 3216

communications@admedus.com